Journal article
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017–2018
Diagnostic microbiology and infectious disease, Vol.97(1), pp.115007-115007
05/2020
DOI: 10.1016/j.diagmicrobio.2020.115007
PMID: 32081523
Abstract
The increasing prevalence of uncommon fungal species and higher antifungal resistance has turned antifungal susceptibility testing into an important monitoring tool. In response, we evaluated the activity of isavuconazole against 522 clinical mold isolates collected worldwide in 2017–2018, including 436 Aspergillus spp. isolates and 86 non-Aspergillus molds. The MIC values using Clinical and Laboratory Standards Institute methods for isavuconazole versus Aspergillus ranged from 0.015 mg/L to >8 mg/L. Isavuconazole showed comparable activity to itraconazole, posaconazole, and voriconazole against A. fumigatus species complex. Most of the Aspergillus spp. isolates tested (>90%) were wild type to all azoles and echinocandins. Eleven isolates were non–wild type to isavuconazole and the other 3 azoles, and 10 of those isolates were from Europe. The azoles and echinocandins showed poor activity against Fusarium and Scedosporium spp. Isavuconazole exhibited excellent activity against most species of Aspergillus and was comparable to itraconazole, posaconazole, and voriconazole against the less common molds.
Details
- Title: Subtitle
- In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017–2018
- Creators
- Shawn A Messer - JMI LaboratoriesCecilia G Carvalhaes - JMI LaboratoriesMariana Castanheira - JMI LaboratoriesMichael A Pfaller - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Diagnostic microbiology and infectious disease, Vol.97(1), pp.115007-115007
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.diagmicrobio.2020.115007
- PMID
- 32081523
- ISSN
- 0732-8893
- eISSN
- 1879-0070
- Grant note
- DOI: 10.13039/100007705, name: Astellas Pharma Global Development, Inc.; name: Pfizer, Inc.
- Language
- English
- Date published
- 05/2020
- Academic Unit
- Epidemiology; Pathology
- Record Identifier
- 9984184003502771
Metrics
8 Record Views